Clinical Institute of Gynecology, Obstetrics, and Neonatology, Hospital Clinic, Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Gynecology, Human Reproduction and Women's Health Group, Barcelona, Spain.
Front Endocrinol (Lausanne). 2024 Oct 28;15:1458846. doi: 10.3389/fendo.2024.1458846. eCollection 2024.
Distinct androgen formulations have been used as gender-affirming hormone treatment, but little is known about the specific changes that may occur in the ovary depending on the testosterone preparation used. The study aims to evaluate the histological modifications of the ovarian tissue and the hormonal changes after gender-affirming surgery based on the testosterone preparation employed, such as testosterone cypionate or undecanoate.
Unicenter transversal cohort study.
Sixty transmasculine persons before and after gender-affirming surgery. A histological examination of the ovaries was conducted, including the follicular population and the characterization of the ovarian stroma. Hormonal status (testosterone, estradiol, FSH, and LH) were also assessed before and after the procedure.
The median age of participants was similar between the two groups (27.9 vs. 26.7 years, p = 0.27). There were no differences in all hormonal determinations before gender-affirming surgery between the groups. After surgery, FSH levels increased significantly, especially in the testosterone undecanoate group compared to the cypionate group (72.3 vs. 38.3 U/L, p = 0.02), consistent with LH determinations (43.0 vs. 23.4 U/L, p = 0.02). However, no regimen modification was required for any individual. No statistical differences were observed in any parameter concerning the follicular population, nor were there any variances in the thickness of the tunica albuginea (p = 0.85) or the proportion of luteinized stromal cells. Nevertheless, there was a tendency toward increased luteinization in the testosterone cypionate group (88.2% vs. 76.9%, p > 0.05).
In a cohort of transmasculine individuals using different androgen preparations, histological analysis of ovarian tissue revealed comparable findings. Both groups exhibited similar follicular populations and comparable modifications in stromal tissue. However, significant differences were observed in hormonal profiles, although no modification in testosterone dosage was needed.
不同的雄激素制剂已被用于性别肯定激素治疗,但对于使用特定的睾酮制剂可能导致卵巢发生的具体变化知之甚少。本研究旨在评估基于所使用的睾酮制剂(如睾酮环戊酯或十一酸睾酮)的性别肯定手术后卵巢组织的组织学改变和激素变化。
单中心横断队列研究。
60 名跨性别男性在性别肯定手术前后。对卵巢进行组织学检查,包括卵泡群体和卵巢基质的特征。还评估了手术前后的激素状态(睾酮、雌二醇、FSH 和 LH)。
两组参与者的中位年龄相似(27.9 岁对 26.7 岁,p = 0.27)。在性别肯定手术前,两组之间的所有激素测定均无差异。手术后,FSH 水平显着升高,尤其是在十一酸睾酮组与环戊酯组之间(72.3 对 38.3 U/L,p = 0.02),与 LH 测定结果一致(43.0 对 23.4 U/L,p = 0.02)。然而,没有个体需要调整治疗方案。在卵泡群体的任何参数或白膜厚度(p = 0.85)或黄体化基质细胞的比例方面均未观察到统计学差异。然而,在睾酮环戊酯组中,黄体化有增加的趋势(88.2%对 76.9%,p > 0.05)。
在使用不同雄激素制剂的跨性别男性队列中,卵巢组织的组织学分析显示出相似的发现。两组均表现出相似的卵泡群体和基质组织的相似变化。然而,在激素谱方面观察到显著差异,尽管不需要改变睾酮剂量。